159 related articles for article (PubMed ID: 27476421)
1. Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors.
Bhide RS; Neels J; Qin LY; Ruan Z; Stachura S; Weigelt C; Sack JS; Stefanski K; Gu X; Xie JH; Goldstine CB; Skala S; Pedicord DL; Ruepp S; Dhar TG; Carter PH; Salter-Cid LM; Poss MA; Davies P
Bioorg Med Chem Lett; 2016 Sep; 26(17):4256-60. PubMed ID: 27476421
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.
Qin LY; Ruan Z; Cherney RJ; Dhar TGM; Neels J; Weigelt CA; Sack JS; Srivastava AS; Cornelius LAM; Tino JA; Stefanski K; Gu X; Xie J; Susulic V; Yang X; Yarde-Chinn M; Skala S; Bosnius R; Goldstein C; Davies P; Ruepp S; Salter-Cid L; Bhide RS; Poss MA
Bioorg Med Chem Lett; 2017 Feb; 27(4):855-861. PubMed ID: 28108251
[TBL] [Abstract][Full Text] [Related]
3. Identification of highly potent and selective PI3Kδ inhibitors.
Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors.
Dugar S; Hollinger FP; Kuila B; Arora R; Sen S; Mahajan D
Bioorg Med Chem Lett; 2015 Aug; 25(16):3142-6. PubMed ID: 26112437
[TBL] [Abstract][Full Text] [Related]
6. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217
[TBL] [Abstract][Full Text] [Related]
8. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
[TBL] [Abstract][Full Text] [Related]
9. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.
Safina BS; Sweeney ZK; Li J; Chan BK; Bisconte A; Carrera D; Castanedo G; Flagella M; Heald R; Lewis C; Murray JM; Nonomiya J; Pang J; Price S; Reif K; Salphati L; Seward EM; Wei B; Sutherlin DP
Bioorg Med Chem Lett; 2013 Sep; 23(17):4953-9. PubMed ID: 23867164
[TBL] [Abstract][Full Text] [Related]
10. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
[TBL] [Abstract][Full Text] [Related]
11. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S
Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.
Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Zhu X; Luo H; Cong X; Wang J; Liu F
Bioorg Med Chem; 2019 Jun; 27(12):2592-2597. PubMed ID: 30926315
[TBL] [Abstract][Full Text] [Related]
13. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
Van Dort ME; Jang Y; Bonham CA; Heist K; Palagama DSW; McDonald L; Zhang EZ; Chenevert TL; Luker GD; Ross BD
Eur J Med Chem; 2022 Feb; 229():113996. PubMed ID: 34802837
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.
Shin Y; Suchomel J; Cardozo M; Duquette J; He X; Henne K; Hu YL; Kelly RC; McCarter J; McGee LR; Medina JC; Metz D; San Miguel T; Mohn D; Tran T; Vissinga C; Wong S; Wannberg S; Whittington DA; Whoriskey J; Yu G; Zalameda L; Zhang X; Cushing TD
J Med Chem; 2016 Jan; 59(1):431-47. PubMed ID: 26652588
[TBL] [Abstract][Full Text] [Related]
15. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Martínez González S; Hernández AI; Álvarez RM; Rodríguez A; Ramos-Lima F; Bischoff JR; Albarrán MI; Cebriá A; Hernández-Encinas E; García-Arocha J; Cebrián D; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2017 Nov; 27(21):4794-4799. PubMed ID: 29017786
[TBL] [Abstract][Full Text] [Related]
17. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis.
Al-Sha'er MA; Al-Aqtash RA; Taha MO
Med Chem; 2019; 15(6):588-601. PubMed ID: 30799792
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR study of potent and selective PI3Kδ inhibitors.
Bui M; Hao X; Shin Y; Cardozo M; He X; Henne K; Suchomel J; McCarter J; McGee LR; San Miguel T; Medina JC; Mohn D; Tran T; Wannberg S; Wong J; Wong S; Zalameda L; Metz D; Cushing TD
Bioorg Med Chem Lett; 2015 Mar; 25(5):1104-9. PubMed ID: 25666823
[TBL] [Abstract][Full Text] [Related]
19. Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
Dumontet C; Beck G; Gardebien F; Haudecoeur R; Mathé D; Matera EL; Tourette A; Mattei E; Esmenjaud J; Boyère C; Nurisso A; Peuchmaur M; Pérès B; Bouchaud G; Magnan A; Monneret G; Boumendjel A
Eur J Med Chem; 2018 Oct; 158():405-413. PubMed ID: 30237123
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.
Jaime-Figueroa S; De Vicente J; Hermann J; Jahangir A; Jin S; Kuglstatter A; Lynch SM; Menke J; Niu L; Patel V; Shao A; Soth M; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2522-6. PubMed ID: 23541670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
